Is high-grade prostate cancer easier to find in smaller prostates because there is more high-grade disease to find?--letter.

摘要

Elliott et al. (1) report that prostate-specific antigen (PSA) performance was significantly better in identifying high-grade disease in men with smaller prostates. They use this observation to support the hypothesis that the increased detection of high-grade disease in the finasteride arm of the Prostate Cancer Prevention Trial was due to an artifact in which the reduction in prostate size made it possible for PSA testing to identify the cancer better in smaller prostates. In their analysis, however, they do not consider another explanation for their findings.